ING Groep NV Has $5.35 Million Stock Holdings in Ralliant Corporation $RAL

ING Groep NV grew its stake in Ralliant Corporation (NYSE:RAL) by 1,169.2% during the third quarter, HoldingsChannel.com reports. The firm owned 122,367 shares of the company’s stock after buying an additional 112,726 shares during the period. ING Groep NV’s holdings in Ralliant were worth $5,351,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Manchester Capital Management LLC bought a new stake in Ralliant in the second quarter valued at about $29,000. Westfuller Advisors LLC bought a new position in Ralliant during the third quarter worth about $26,000. UMB Bank n.a. acquired a new position in shares of Ralliant during the 3rd quarter worth about $29,000. Evermay Wealth Management LLC bought a new stake in shares of Ralliant in the 2nd quarter valued at about $32,000. Finally, Webster Bank N. A. acquired a new stake in shares of Ralliant in the 3rd quarter valued at approximately $31,000.

Ralliant Stock Down 0.1%

Shares of RAL stock opened at $42.68 on Friday. The firm has a fifty day moving average of $50.93 and a 200-day moving average of $46.59. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a market capitalization of $4.81 billion and a price-to-earnings ratio of 21.78.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to the consensus estimate of $543.04 million. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant’s payout ratio is 10.20%.

Insider Transactions at Ralliant

In other news, Director Kate Mitchell acquired 2,350 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was acquired at an average cost of $42.48 per share, for a total transaction of $99,828.00. Following the completion of the acquisition, the director owned 8,411 shares in the company, valued at $357,299.28. This represents a 38.77% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Anelise Angelino Sacks bought 2,000 shares of the business’s stock in a transaction on Monday, February 9th. The stock was purchased at an average price of $41.25 per share, for a total transaction of $82,500.00. Following the purchase, the director directly owned 5,403 shares in the company, valued at approximately $222,873.75. This represents a 58.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 8,145 shares of company stock valued at $332,233 over the last three months.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Company insiders have been buying shares, signaling management confidence — Director Kate Mitchell purchased 2,350 shares at ~$42.48 and Director Anelise Angelino Sacks bought 2,000 shares (disclosed in SEC filings). These purchases can support the stock and signal perceived undervaluation. Kate Mitchell SEC Filing Anelise Angelino Sacks SEC Filing
• Neutral Sentiment: Management will present at upcoming investor conferences (Citi and Barclays on Feb 17–18), offering a platform to clarify strategy and guidance — useful for investors seeking more detail but not an immediate catalyst. Conference Announcement
• Neutral Sentiment: Several sell‑side firms trimmed price targets (Barclays, Citigroup, Truist, Oppenheimer) — these lower targets reduce near‑term enthusiasm but many analysts retained positive ratings, leaving mixed guidance for investors. Barclays / Analyst Notes
• Negative Sentiment: Ralliant disclosed a roughly $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment and reduced FY2026 guidance — a material accounting charge and weaker outlook that hit fundamentals and triggered large analyst re‑ratings. Impairment / Guidance Report
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Block & Leviton, Kaplan Fox and others) have opened or publicized investigations into possible securities‑law violations related to the impairment timing/disclosure — raising litigation, regulatory and reputational risk. Kessler Topaz PR Block & Leviton Alert
• Negative Sentiment: Short interest rose sharply (~+58.7% in January to ~3.75M shares), amplifying downside pressure and intraday volatility as bearish positioning increases the risk of further selling on negative headlines.
• Negative Sentiment: Zacks downgraded Ralliant to a “strong sell,” adding to negative analyst momentum and likely contributing to selling pressure. Zacks Note

Wall Street Analyst Weigh In

Several research firms recently weighed in on RAL. Citigroup reduced their price objective on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Truist Financial reduced their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Zacks Research cut shares of Ralliant from a “hold” rating to a “strong sell” rating in a research report on Monday. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a research note on Friday, February 6th. Finally, Barclays decreased their target price on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a research note on Monday. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $50.50.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.